Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

| Name | Name of entity Proteomics International Laboratories Ltd | | |
|--------------|---|--|--|
| Prote | | | |
| ABN | | | |
| 78 16 | 9 979 971 | | |
| We (| the entity) give ASX the followin | g information. | |
| | 1 - All issues oust complete the relevant sections (attack | th sheets if there is not enough space). | |
| 1 | ⁺ Class of ⁺ securities issued or to be issued | Not applicable | |
| 2 | Number of *securities issued or to be issued (if known) or maximum number which may be issued | Not applicable | |
| 3 | Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion) | Not applicable | |

⁺ See chapter 19 for defined terms.

| 4 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | Not applicable |
|----|---|----------------|
| 5 | Issue price or consideration | Not applicable |
| 6 | Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) | Not applicable |
| 6a | Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and | No |
| | comply with section 6i | |
| 6b | The date the security holder resolution under rule 7.1A was passed | Not applicable |
| 6c | Number of *securities issued without security holder approval under rule 7.1 | Nil |

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

Number of *securities issued 6d Not applicable with security holder approval under rule 7.1A Number of *securities issued 6e Nil with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of *securities issued Nil under an exception in rule 7.2 If *securities issued under rule Not applicable 6g 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the tissue date and both values. Include the source of the VWAP calculation. 6h If *securities were issued under Not applicable rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to **ASX Market Announcements** Calculate the entity's remaining 6i 7.1: 5,303,195 issue capacity under rule 7.1 and 7.1A : Not applicable rule 7.1A – complete Annexure 1 and release to ASX Market Announcements *Issue dates Not applicable Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. Number +Class Number and +class of all Fully paid ordinary 8 21,353,072. +securities quoted on ASX shares. (including the +securities in section 2 if applicable) Options exercisable 12,622,181. at \$0.20 each on or before March 31 2018.

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

| Number | +Class |
|------------|------------------------|
| 29,251,563 | Fully paid ordinary |
| | shares. |
| 3,110,000 | Options exercisable |
| | at \$ 0.20 expiring at |
| | 31 March 2018. |
| 175 | Performance Rights |
| | with nil exercise |
| | price, each vests into |
| | 100,000 shares |
| | subject to specific |
| | vesting conditions |
| | and vesting cap. |

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

| Not applicable | | |
|----------------|--|--|
| | | |

Part 2 - Pro rata issue

Questions 11 to 33 Not Applicable

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

| 34 | Type of *securities (tick one) |
|-----|--|
| (a) | *Securities described in Part 1 |
| (b) | All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities |

Entities that have ticked box 34(a)

Questions 35 to 37 - Not Applicable

Entities that have ticked box 34(b)

Number of *securities for which *quotation is sought

| 828,952 | | | |
|---------|--|--|--|
| | | | |

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

⁺Class of *securities for which quotation is sought

Fully paid ordinary shares

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

Yes

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another *security, clearly identify that other *security)

End of restriction period: 8 April 2016

42 Number and *class of all *securities quoted on ASX (including the *securities in clause 38)

| Number | +Class |
|-------------|--|
| 21,353,072. | Fully paid ordinary shares. |
| 12,622,181. | Options exercisable at \$0.20 each on or before 31 March 2018. |

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the *securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

| Sign here: | | Date: 8 April 2016 | |
|-------------|-------------------|--------------------|--|
| J | Company secretary | • | |
| Print name: | Karen Logan | | |
| | | | |

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

| Rule 7.1 – Issues exceeding 15% of capital | | |
|---|--|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue | 35,331,453 | |
| Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval Number of partly paid *ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid *ordinary securities cancelled during that 12 month period | 1,250 fully paid ordinary shares issued on 27 November 2015, exception 4. 7,500 fully paid ordinary shares issued on 7 December 2015, exception 4. 13,750 fully paid ordinary shares issued on 16 February 2016, exception 4. 682 fully paid ordinary shares issued on 31 March 2016, exception 4. Nil | |
| "A" | 35,354,635 | |

⁺ See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A" | | | |
|---|---|--|--|
| "B" | 0.15 | | |
| | [Note: this value cannot be changed] | | |
| Multiply "A" by 0.15 | 5,303,195 | | |
| Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used | | | |
| Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued: | Nil | | |
| Under an exception in rule 7.2 | | | |
| Under rule 7.1A | | | |
| With security holder approval under rule 7.1 or rule 7.4 | | | |
| Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | | |
| "C" | Nil | | |
| Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1 | | | |
| "A" x 0.15 | 5,303,195 | | |
| Note: number must be same as shown in Step 2 | | | |
| Subtract "C" | Nil | | |
| Note: number must be same as shown in Step 3 | | | |
| Total ["A" x 0.15] – "C" | 5,303,195 | | |
| | [Note: this is the remaining placement capacity under rule 7.1] | | |

⁺ See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013

Part 2

| re from which the placement | | |
|--|--|--|
| • | | |
| Not applicable | | |
| | | |
| | | |
| 0.10 | | |
| Note: this value cannot be changed | | |
| Not applicable | | |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used | | |
| Not applicable | | |
| Not applicable | | |
| | | |

⁺ See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A | | |
|---|--|--|
| "A" x 0.10 | Not applicable | |
| Note: number must be same as shown in Step 2 | | |
| Subtract "E" | Not applicable | |
| Note: number must be same as shown in Step 3 | | |
| Total ["A" x 0.10] – "E" | Not applicable | |
| | Note: this is the remaining placement capacity under rule 7.1A | |

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.